Pain

 
Study: State Laws Intended to Reduce Opioid Prescribing had Little Impact on Prescribing Practices
April 27, 2022

Study addresses the concern that state opioid prescription laws may lead to some chronic pain patients missing out on critical pain treatment.

"Migraine is a Tremendously Rewarding Disease to Treat"
April 22, 2022

Yale headache specialist Christopher Gottschalk, MD, talks about the opportunities to make a marked difference in the quality of patients' lives.

Chronic Pain Management in America: A 10-question Quiz
April 14, 2022

A cross-sectional study found that US adults with chronic pain use a variety of pain management techniques, including opioid and nondrug therapies. Key results in this 10-question quiz.

Should Medicare Cover Medical Marijuana: Medicare Recipients Respond
April 13, 2022

Medical cannabis is already popular with Medicare recipients and many fear insurance coverage will drive up the cost. Find out what else a new survey found.

Primary Care is the Answer to the Migraine Care Gap, Says Headache Specialist
April 12, 2022

US patients diagnosed with migraine: 40 million. US headache specialists: 600. Primary care is the answer, according to Christopher Gottschalk, MD.

CGRP Inhibition for Migraine: Side Effects are Few but Pay Attention for These
April 11, 2022

The CGRP inhibitor class of injectable migraine preventive agents has a very favorable side effect profile but the drugs do come with some cautions, says Christopher Gottschalk, MD.

Rimegepant for Acute Migraine May Reduce Use of, Reliance on Opioids: New Data
April 07, 2022

Opioid refills were reduced by ~40% in the 9 months following an initial prescription for rimegepant among patients with migraine, a new study found.

Oral Gepants: Christopher Gottschalk, MD Tells the Origin Story, Highlights Broad Efficacy
April 01, 2022

The migraine-specific oral gepants are proving effective across the continuum of migraine frequency. Dr Gottschalk talks about their shaky start.

Atogepant: Pivotal Phase 3 Study Meets Primary Endpoint for Preventive Treatment of Chronic Migraine
March 10, 2022

Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.

Migraine Management Pearls for Primary Care with Neurologist Jessica Ailani, MD
March 10, 2022

Consider migraine screening for all women aged 20 to 50 years, suggests Ailani; you'll likely find a majority of them have migraine. More pearls follow.